Asset
DIROXIMEL FUMARATE
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02634307 | phase3 | completed | 2015-12-10 | 2021-06-01 | Biogen | A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 |
| NCT05083923 | phase3 | completed | 2021-11-18 | 2024-09-11 | Biogen | A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) |
| NCT05127564 | phase1 | completed | 2021-12-03 | 2022-06-09 | Biogen | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants |
| NCT07483632 | phase3 | not_yet_recruiting | 2026-11-16 | 2034-07-28 | Biogen | A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) |
| NCT03093324 | phase3 | completed | 2017-03-15 | 2019-06-27 | Biogen | A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 211855 | NDA | BIOGEN INC |
Marketed products (1)
- VUMERITY